EKSOHIGH SIGNALFINANCIAL10-K

EKSO faces severe financial distress with cash plummeting 82% to just $1.2M while gross profit declined 28% and operating losses widened significantly.

The dramatic cash burn combined with widening operating losses creates an immediate liquidity crisis that threatens the company's ability to continue operations without additional funding. With only $1.2M in cash remaining and mounting losses, EKSO will likely need to raise capital urgently or face potential bankruptcy.

Comparing 2026-02-23 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

EKSO's financial position deteriorated across all major metrics, with the most alarming being the 82% collapse in cash to just $1.2M alongside a 28% decline in gross profit to $6.8M. Operating losses widened to -$13.3M despite R&D expense reductions, while interest expense nearly doubled and capital expenditures surged 408%, indicating the company is burning through its remaining resources at an unsustainable rate. The overall picture signals acute financial distress requiring immediate capital infusion to avoid insolvency.

FINANCIAL STATEMENT CHANGES
SG&A Expense
P&L
+860.5%
157$2K

SG&A up 860.5% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Capital Expenditure
Cash Flow
+408.1%
$37K$188K

Capital expenditure jumped 408.1% — major investment cycle underway; assess returns on deployment.

Interest Expense
P&L
+93.6%
$156K$302K

Interest expense surged 93.6% — significant debt increase or rising rates materially impacting earnings.

Cash & Equivalents
Balance Sheet
-82%
$6.5M$1.2M

Cash declined 82% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Stockholders Equity
Balance Sheet
-29%
$12.7M$9.0M

Equity decreased 29% — buybacks or losses reducing book value, monitor solvency ratios.

Gross Profit
P&L
-28%
$9.5M$6.8M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Operating Income
P&L
-27.4%
-$10.5M-$13.3M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Current Assets
Balance Sheet
-25.4%
$18.8M$14.0M

Current assets declined 25.4% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-24.5%
$26.7M$20.1M

Total assets contracted 24.5% — asset sales, write-downs, or balance sheet optimization underway.

R&D Expense
P&L
-21.8%
$3.9M$3.0M

R&D spending cut 21.8% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-02-23
PRIOR — 2025-03-03
ADDED
false --12-31 FY 2025 We perform a formal risk assessment each year.
As part of the Company's risk assessment, we consider the potential for cybersecurity threats, including but not limited to interruptions, outages and breaches to its operational and financial systems.
We have policies, processes, internal controls and tools to assess, identify, and manage material risks from potential cybersecurity threats.
We utilize a combination of cybersecurity awareness training, manual processes, specialized software and automated tools, and third-party assessments to build our cybersecurity program.
We engage third-party service providers, with significant information technology and cybersecurity experience, to assist with designing, implementing and managing our information technology infrastructure and cybersecurity program.
+7 more — sign up free →
REMOVED
The weighted average number of common shares outstanding, used in the basic and diluted Net loss per share as of December 31, 2024, includes the weighted average effect of the Pre-Funded Warrant issued in connection with the September 2024 firm commitment underwritten public offering, the exercise of which requires nominal consideration for the delivery of the shares of common stock.
Capitalization and Equity Structure Warrants for additional information regarding the warrants.
As of February 28, 2025, the registrant had 24,824,762 outstanding shares of common stock.
We continue to explore business development initiatives to fuel growth and long-term value and are committed to helping people improve mobility and live healthier lives through combining the use of technology with advanced rehabilitative programs.
We expect that Nomad will continue to be available in limited volumes for non-Company-sponsored clinical studies in 2025.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →